<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03422263</url>
  </required_header>
  <id_info>
    <org_study_id>Bernerklinik</org_study_id>
    <nct_id>NCT03422263</nct_id>
  </id_info>
  <brief_title>Performance Under SGLT-2-Inhibitors in Humans</brief_title>
  <acronym>PUSH</acronym>
  <official_title>Early Performance in Patients With Type-II-Diabetes Mellitus Under New Treatment With SGLT-2-Inhibitors Compared to Control Groups.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Berner Klinik Montana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Berner Klinik Montana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PUSH Study is conceived to investigate the early effects of SGLT-2-Inhibitors on the
      physical performance of patients with Type-II-Diabetes mellitus compared to patients under
      other therapy regimes. Patients shall be divided into 3 groups: I - Patients with type II
      diabetes mellitus under new treatment with an SGLT2-Inhibitor. II - Patients with type II
      diabetes mellitus without SGLT-2- Inhibitor medication. III - Patients without type II
      diabetes mellitus but with similar comorbidities to the previous groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SGLT-2-Inhibitors have been shown to improve cardiovascular outcomes in patients with type II
      diabetes mellitus. Present evidence shows this effect to be not directly related to better
      serum glucose levels because the effect was measurable within several days of initiation of
      the treatment.

      In a prospective single-centre double-blinded comparative observational study, other aspects
      of the effect of SGLT-2-Inhibitors shall be analyzed from patient registry, particularly the
      physical performance of patients under new treatment with SGLT-2-Inhibitors. Patient consent
      will be sort for the analysis of clinical data during the duration of stay.

      Patients included in the registry suitable for analysis shall be divided into 3 groups: I -
      Patients with type II diabetes mellitus under new treatment with an SGLT2-Inhibitor. II -
      Patients with type II diabetes mellitus without SGLT-2- Inhibitor medication. III - Patients
      without type II diabetes mellitus but with similar comorbidities to the previous groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>28 Days</target_duration>
  <primary_outcome>
    <measure>6 minute walk test</measure>
    <time_frame>28 days</time_frame>
    <description>Change in distance covered.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle anatomy</measure>
    <time_frame>28 days</time_frame>
    <description>Change in muscle architecture parameter (MAP) measured as the mid-thigh diameter of the medial vastus muscle using B-mode sonography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle physiology</measure>
    <time_frame>28 days</time_frame>
    <description>Muscle strength measured as hand grip in Newton using a hand dynamometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical</measure>
    <time_frame>28 days</time_frame>
    <description>change in routine laboratory parameter related to muscle status using measurements of creatinine kinase in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Assessment</measure>
    <time_frame>28 days</time_frame>
    <description>Change in fatigue using a Fatigue Score questionnaire (FSMC) as assessed by patient.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Patients with T2DM under new therapy with SGLT-2-Inhibitors</arm_group_label>
    <description>Patients with T2DM under new therapy with SGLT-2-Inhibitors (Empagliflozin 10 mg per day, Dapagliflozin 10 mg per day, Canagliflozin 100 mg per day) at baseline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with T2DM without SGLT-2-Inhibitors.</arm_group_label>
    <description>Patients with T2DM without therapy with SGLT-2-Inhibitors (Empagliflozin 10 mg per day, Dapagliflozin 10 mg per day, Canagliflozin 100 mg per day) at baseline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without T2DM manifesting similar comorbidities</arm_group_label>
    <description>Patients without T2DM manifesting similar comorbidities (Haemoglobin value, renal function, similar body mass index, cardiovascular disease profile)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Ambulatory patients above the age of 40 who provide informed consent.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consent

          -  ambulatory patients

        Exclusion Criteria:

          -  relevant limitations in movement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Devine S Frundi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Berner Klinik Montana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Devine S Frundi, MD</last_name>
    <phone>+41 27 485 5277</phone>
    <email>devine.frundi@bernerklinik.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Berner Klinik Montana</name>
      <address>
        <city>Crans-Montana</city>
        <state>Valais</state>
        <zip>3963</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Devine S Frundi, MD</last_name>
      <phone>+41 274855242</phone>
      <email>devine.frundi@bernerklinik.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Berner Klinik Montana</investigator_affiliation>
    <investigator_full_name>Devine Frundi</investigator_full_name>
    <investigator_title>Lead physician of internal medicine (Leitender Arzt Medizin)</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus, SGLT-2-Inhibitors, Empagliflozin, Canagliflozin, Dapagliflozin, 6-minute walk test.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Canagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Results of the study for academic purposes for trainees to get an academic degree within Switzerland.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

